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Uncoupling of p97 ATPase activity 
has a dominant negative effect on 
protein extraction
Halley B. Rycenga1, Kelly B. Wolfe1, Elizabeth S. Yeh2 & David T. Long1
p97 is a highly abundant, homohexameric AAA+ ATPase that performs a variety of essential cellular 
functions. Characterized as a ubiquitin-selective chaperone, p97 recognizes proteins conjugated to 
K48-linked polyubiquitin chains and promotes their removal from chromatin and other molecular 
complexes. Changes in p97 expression or activity are associated with the development of cancer and 
several related neurodegenerative disorders. Although pathogenic p97 mutations cluster in and around 
p97’s ATPase domains, mutant proteins display normal or elevated ATPase activity. Here, we show that 
one of the most common p97 mutations (R155C) retains ATPase activity, but is functionally defective. 
p97-R155C can be recruited to ubiquitinated substrates on chromatin, but is unable to promote 
substrate removal. As a result, p97-R155C acts as a dominant negative, blocking protein extraction by 
a similar mechanism to that observed when p97’s ATPase activity is inhibited or inactivated. However, 
unlike ATPase-deficient proteins, p97-R155C consumes excess ATP, which can hinder high-energy 
processes. Together, our results shed new insight into how pathogenic mutations in p97 alter its cellular 
function, with implications for understanding the etiology and treatment of p97-associated diseases.
p97/Cdc48/VCP (valosin-containing protein) is a highly abundant molecular chaperone that performs a variety 
of essential functions throughout the cell1–3. p97 forms a homo-hexameric AAA+ ATPase that relies on ATP 
hydrolysis to remodel and disassemble protein complexes4. p97 is recruited to substrate proteins by different 
binding partners that interact with K48-linked polyubiquitin chains5,6. K48-linked chains act as the primary 
signal for p97 recruitment and protein remodeling, although mono-ubiquitin and branched or mixed ubiquitin 
linkages may play additional roles in regulating p97 activity7,8. p97 interacts with multiple components of the 
26S proteasome and has been shown to facilitate proteasomal degradation of various proteins9–11. However, p97 
substrates can also be de-ubiquitinated in the absence of degradation and potentially recycled for future use12,13.
In cells, p97 plays an essential role in maintaining protein homeostasis as part of the endoplasmic 
reticulum-associated degradation (ERAD) pathway3,14. Misfolded proteins that accumulate in the endoplasmic 
reticulum (ER) due to error or stress are recognized by chaperones and directed to ubiquitin ligases that catalyze 
formation of K48-linked polyubiquitin chains15. p97 then facilitates extraction of ubiquitinated proteins from ER 
or ERAD-associated complexes, followed by protein degradation in the cytoplasm16. p97 also plays an analogous 
role in the nucleus called ubiquitin-dependent extraction from chromatin (UDEC)17,18. Extraction and degra-
dation of chromatin-bound proteins is used to regulate dynamic changes in chromatin structure and function 
during DNA replication, damage signaling, gene expression, and chromosomal segregation2,12,19–24.
Due to its central role in many fundamental cellular pathways, disruption of p97 function can lead to several 
forms of disease. p97 expression is frequently up-regulated in multiple cancers and correlates with poor prognosis 
in patients25,26. These observations suggested that many cancers rely on p97 to manage cellular stress associated 
with tumorigenesis and that targeting p97 could improve anti-cancer therapeutics27,28. A series of p97 inhibitors 
have been developed that target p97’s ATPase activity, including DBeQ.29, ML24030, NMS-87331, and CB-508332. 
Although each drug is highly active in vitro, CB-5083 has shown the most promise for in vivo studies33 and use in 
clinical trials (NCT02223598 and NCT02243917).
Each p97 subunit contains two tandem ATPase domains (D1 and D2) that support inter-subunit interaction 
and ATP hydrolysis34,35. The D1 and D2 domains are flanked by an N-domain and flexible C-terminus that serve 
as binding sites for different p97 cofactors5,36. Although p97 is essential for cellular viability13,37,38, heterozygous 
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missense mutations can lead to a collection of related neurodegenerative diseases characterized by multisystem 
proteinopathy, including frontotemporal dementia (FTD), inclusion body myopathy (IBM), and Paget’s disease of 
bone (PD)39,40. p97 mutations may also contribute to the development of amyotrophic lateral sclerosis (ALS)41,42, 
a progressive neurodegenerative disease affecting the brain and spinal cord.
Pathogenic mutations of p97 are most commonly found within the N-domain, but are also present in and 
around the D1 and D2 ATPase domains43. The majority of these p97 mutations were shown to convey normal 
or elevated ATPase activity in vitro39,44, suggesting that many disease symptoms result from elevated or unreg-
ulated p97 activity39,45. One of the most frequently mutated sites in p97 is arginine 155 (R155), located within 
the N-domain40. Here, we show that a common R155 mutation, R155C, leaves p97’s ATPase activity intact, but 
functionally uncouples it from protein extraction. As a result, p97-R155C acts as a dominant negative, remaining 
bound to ubiquitinated substrates and consuming excess ATP. These results reconcile conflicting biochemical and 
cellular observations, providing new insight on the molecular consequences of p97 dysfunction.
Results
Disruption of p97’s ATPase activity prevents its release from chromatin-bound substrates. To 
investigate how p97’s ATPase activity affects its interaction with potential substrates, we analyzed recruitment 
of p97 to plasmids incubated in Xenopus egg extract. When plasmid substrates are added to extract, they are 
rapidly chromatinized due to an abundance of histones present in egg cytoplasm46,47. Chromatinization creates 
a scaffold for numerous dynamic protein interactions, including those that support chromatin remodeling and 
DNA compaction48. Extract was supplemented with buffer or the p97 inhibitor CB-5083 (p97i). CB-5083 is a 
highly selective, competitive inhibitor that targets p97’s D2 ATPase domain32. Undamaged plasmid DNA (pDNA) 
was incubated in extract, and then DNA-bound proteins were isolated by plasmid pull-down and visualized by 
Western blot. Extract treated with buffer showed little or no p97 accumulation on DNA, even after 180 min-
utes (Fig. 1A, lanes 2–5). However, in the presence of p97i, the level of DNA-bound p97 increased dramatically 
(Fig. 1A, lanes 6–9). p97 inhibition also led to an increase in ubiquitin on DNA (Fig. 1A, compare lanes 2–5 and 
6–9), suggesting that removal of ubiquitinated proteins was defective13. Consistent with this inference, we saw 
that a known p97 substrate, Aurora-B49, was enriched on DNA in the presence of p97i (Fig. S1A). We then pre-
treated extract with the de-ubiquitinase inhibitor Ubiquitin Vinyl Sulfone (UbVS), which leads to depletion of 
free ubiquitin12,50–52. Loss of ubiquitin prevented the accumulation of both ubiquitinated proteins and p97 on 
DNA (Fig. 1A, lanes 10–13). Similar results were obtained using the p97 inhibitor NMS-873 (Fig. S2A–C), an 
allosteric non-competitive inhibitor that also blocks p97’s ATPase activity31.
We then asked whether p97 accumulation was dependent on the formation of K48-linked polyubiquitin 
chains, which act as the primary signal for p97-dependent protein extraction53,54. Extract was supplemented 
with p97i and either wild-type ubiquitin (Ub) or mutant ubiquitin containing an arginine substitution at lysine 
48 (Ub-K48R). Compared to reactions supplemented with Ub, Ub-K48R led to a severe reduction in both 
DNA-bound p97 and ubiquitin (Fig. 1D, compare lanes 3–6 and 7−10). Thus, inhibiting p97’s ATPase activity in 
extract leads to its accumulation on DNA through interaction with putative substrates modified with K48-linked 
polyubiquitin chains. Although not all ubiquitinated proteins bound to DNA are likely to be p97 substrates, our 
results indicate that accumulation of p97 on DNA occurs through its interaction with these proteins.
In yeast, ATP hydrolysis was shown to be essential for the release of Cdc48 from ubiquitinated substrates16. 
To test whether inhibiting p97’s ATPase activity also had an effect on the interaction between p97 and its sub-
strates, we first incubated pDNA in extract containing p97i for 180 minutes. DNA was then isolated from extract 
by plasmid pull-down and suspended in buffer with or without ATP. Retention of p97 on bead-bound DNA was 
then visualized by Western blot over time. When incubated in the absence of ATP, the level of DNA-bound p97 
decreased by ~70% within 180 minutes (Fig. 2A, lanes 4–7; Fig. 2C, blue trace). In the presence of ATP, p97 dis-
placement occurred more quickly, decreasing by ~90% within 180 minutes (Fig. 2A, lanes 9–12; Fig. 2C, green 
trace). When p97i was included in the incubation buffer, the majority of p97 remained bound at 180 minutes with 
or without addition of ATP (Fig. 2B, lanes 4–7 and 9–12; Fig. 2C gold and red traces). Using the p97 inhibitor 
NMS-873, we also saw that inhibition reduced p97’s displacement from DNA in the absence of ATP (Fig. S2D,E). 
Taken together, these results indicate that loss of ATPase activity influences p97 accumulation in two ways; both 
by increasing the number of DNA-bound substrates that p97 can interact with and by preventing the release of 
p97 from those substrates.
Cellular localization of p97 is revealed by protein inhibition. Our in vitro results predict that loss 
of ATPase activity leads to increased accumulation of p97 on chromatin, due to sequestration by ubiquitinated 
substrates. Although the cellular localization of some p97 mutants has been investigated55,56, the specific role that 
ATPase activity plays in protein localization is not well defined. We hypothesized that p97 inhibition first leads to 
sequestration of the protein on existing ubiquitinated substrates, prior to substrate accumulation and widespread 
cellular dysfunction57,58. Thus, limited exposure to p97i could provide an indicator of normal p97 utilization 
within cells. To investigate how p97 inhibition influences its sub-cellular localization in cells subject to differ-
ent levels of chromatin stress, we treated non-transformed MCF-10A breast epithelial cells and MCF-7 breast 
adenocarcinoma cells with p97i for 24 hours and then visualized p97 by immunofluorescence. Cells were each 
treated with a “low” dose of p97i (1 μM), as well as a higher dose (2 μM) that was sufficient to induce expression 
of CHOP, an apoptosis-associated stress response marker59 (Fig. S4A,B). For each treatment, the relative fraction 
of total p97 that was localized to the nucleus was quantified and normalized to that observed in untreated cells. At 
the low dose, p97 inhibition had opposite effects on the relative fraction of nuclear p97 in MCF-10A cells, which 
decreased by 20% (Fig. 3A,B), and MCF-7 cells, which increased by 24% (Fig. 3C,D). These observations support 
the idea that cancer cells exhibit increased nuclear stress that is alleviated by p97. At the high dose of p97i, the 
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nuclear fraction of p97 increased in MCF-10A cells relative to the low dose and remained elevated in MCF-7 
cells, suggesting that induction of apoptosis causes both cell types to retain or re-localize p97 within the nucleus.
To further investigate how p97 is localized within cells, MCF-7 and MCF-10A cells were treated with a range 
of p97i concentrations, fractionated to isolate different cellular compartments, and then visualized by Western 
blot. In MCF-10A cells, lower doses of inhibitor led to an increase in cytoplasmic p97 and decreases in both 
soluble nuclear and chromatin-bound fractions (Fig. 4A,C–E, gray trace). These trends reversed at higher doses, 
coinciding with induction of CHOP (Fig. S4A). In MCF-7 cells, p97i led to a dose-dependent reduction in cyto-
plasmic p97, and increases in both the soluble nuclear and chromatin-bound fractions (Fig. 4B,C–E, cyan trace). 
Taken together, both immunofluorescence (Fig. 3) and fractionation (Fig. 4) data indicate that MCF-10A and 
MCF-7 cells utilize p97 in different ways, leading to distinct patterns of sub-cellular localization when the protein 
is sequestered on ubiquitinated substrates.
The R155C mutation functionally uncouples ATPase activity from protein extraction. To test 
how pathogenic mutations in p97 affect its interaction with chromatin-bound substrates, extract was supple-
mented with recombinant hexameric complexes consisting of wild-type p97 (p97-WT), an ATPase-dead mutant 
Figure 1. Inhibition of p97 leads to substantial accumulation on chromatin-bound substrates. (A) pDNA 
was incubated in extract supplemented with buffer, the p97 inhibitor CB-5083 (p97i), or p97i and the de-
ubiquitinase inhibitor UbVS. DNA-bound proteins were isolated by plasmid pull-down at various times and 
visualized by Western blot with the indicated antibodies. (B,C) Relative quantitation of DNA-bound p97 (B) 
and DNA-bound ubiquitin (C) from three biological replicates. Values are normalized to peak accumulation in 
the +Buffer reaction and error bars represent +/− one standard deviation. (D) pDNA was incubated in extract 
supplemented with p97i and either wild-type ubiquitin (Ub) or K48R mutant ubiquitin (Ub-K48R). DNA-
bound proteins were isolated by plasmid pull-down at various times and visualized by Western blot with the 
indicated antibodies. Full Western blot images are available in Fig. S1.
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(p97-D1D2)60, or p97 containing an R155C mutation (p97-R155C). R155C is one of the most frequently identi-
fied p97 mutations and retains ATPase activity in vitro (Fig. S6)44,61. pDNA was incubated in extract for the time 
indicated, and then DNA-bound proteins were isolated by plasmid pull-down and visualized by Western blot. 
Compared to wild-type p97, both the D1D2 and R155C mutants showed an increase in the accumulation of 
DNA-bound p97 and ubiquitin (Fig. 5A, compare lanes 2–5 with 6–9 and 10–13). Similar defects have also been 
observed in mouse models carrying different p97-R155 mutations61–63. These results indicate that both the D1D2 
and R155C p97 proteins have a dominant negative effect on substrate unloading similar to that observed in the 
presence of p97i (Fig. 1A, lanes 6–9).
Notably, the accumulation of DNA-bound ubiquitin peaked earlier in the presence of p97-R155C (Fig. 5A, 
lane 11), indicating a defect not observed in the presence of p97i or p97-D1D2. Accumulation of histone H3 
on pDNA was also decreased in the presence of p97-R155C (Fig. 5A, compare lanes 2–5 with 6–9 and 10–13). 
Histone loading is not dependent on p97 (Fig. 1A), suggesting that nucleosome assembly was compromised by 
an indirect mechanism. We speculated that constitutive activity of p97-R155C’s ATPase domain may consume 
energy required for normal plasmid chromatinization in extract64. When the p97-R155C reaction was supple-
mented with excess ATP regenerating mix (containing ATP, phosphocreatine, and creatine phosphokinase), the 
early accumulation of DNA-bound ubiquitin was reduced and histone H3 levels increased (Fig. 5D, compare 
lanes 9 and 10). Additional ATP also produced a mild increase in histone H3 loading in p97-WT reactions, but 
had no effect on the early accumulation of ubiquitin or histone H3 in p97-D1D2 reactions (Fig. 5D, compare lanes 
1–2 and 4–5). These results indicate that the R155C mutation creates a requirement for additional ATP that can 
disrupt high-energy consuming processes like chromatinization.
To determine whether the R155C mutation also affects p97’s interaction with DNA-bound substrates, we incubated 
pDNA in extract supplemented with p97-WT, p97-D1D2, or p97-R155C for 180 minutes. DNA was then isolated 
from extract by plasmid pull-down and further incubated in buffer with or without ATP. Consistent with Fig. 5A, p97 
accumulation was highly elevated in the presence of p97-D1D2 and p97-R155C, but showed little or no accumulation 
with p97-WT (Fig. 6A–C, lane 3). When pDNA was further incubated in buffer with or without ATP, both p97-D1D2 
and p97-R155C remained bound to DNA throughout the reaction (Fig. 6B,C, lanes 4–6 and 8–10). Thus, both mutant 
proteins were unable to utilize ATP to promote displacement from chromatin. Taken together, Figs 5 and 6 demonstrate 
that the R155C mutation functionally uncouples p97’s ATPase activity from its protein extraction function.
Figure 2. p97 inhibition prevents its release from DNA. (A,B) pDNA was incubated in extract supplemented 
with CB-5083 (p97i). After 180 minutes, DNA was isolated by plasmid pull-down and then incubated in buffer 
+/− ATP (A), or buffer containing p97i +/− ATP (B). At various times, DNA-bound proteins were recovered 
and visualized by Western blot with the indicated antibodies. (C) Quantitation of DNA-bound p97 from three 
biological replicates. Values are normalized to accumulation after the 180 minute pre-incubation with p97i 
(0 minutes, lane 3) and error bars represent +/− one standard deviation. Full Western blot images are available 
in Fig. S3.
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Discussion
ATPase inactivation creates a dominant negative effect. p97 is an essential protein chaperone whose 
functions are tightly regulated to maintain cellular homeostasis. Using Xenopus egg extracts, we found that inhib-
iting p97’s ATPase activity led to a dramatic increase in the accumulation of both p97 and ubiquitinated proteins 
on DNA (Fig. 1A, lanes 6–9). Accumulation of p97 was dependent on ubiquitin (Fig. 1A, lanes 10–13) and the 
formation of K48-linked polyubiquitin chains (Fig. 1D), arguing that it is recruited to DNA through interaction 
with DNA-bound substrates. Thus, in the context of this system, p97’s normal function is to prevent the accumu-
lation of ubiquitinated proteins on DNA.
Interestingly, the increase in DNA-bound ubiquitin was relatively mild compared to that of p97 (Fig. 1B,C). Using a 
dilution experiment to monitor p97 binding affinity for its DNA-bound substrates, we saw that p97 inhibition stabilized 
DNA-bound p97 in the absence of ATP (Fig. 2A,B, lanes 4–7). In yeast, ATP hydrolysis was shown to be essential for the 
release of Cdc48 from ubiquitinated substrates16, suggesting that an induced conformational change helps to disrupt 
the cofactor-ubiquitin interaction that targets p97 to its substrates. We showed previously that failure to extract a p97 
substrate from chromatin can lead to the formation of highly extended polyubiquitin chains12,29,37. Together, these data 
support a model where p97 inhibition stabilizes the binding of multiple p97 complexes to a single, extended ubiquitin 
chain. As a result, inactive p97 complexes likely shield the substrate from extraction, thereby contributing to a dominant 
negative effect.
Figure 3. Cellular localization of p97. (A) MCF-10A cells were plated for 24 hours and then treated with buffer or the 
indicated concentrations of CB-5083 (p97i). 24 hours after treatment, cells were visualized by immunofluorescence, 
with representative images shown (A). (B) Quantitation of relative nuclear abundance of p97 in (A), normalized to 
the mean in buffer-treated cells. (C,D) MCF-7 cells were treated, visualized (C), and quantitated (D), as in (A,B). 
Doses above 1.0 μM CB-5083 show elevated levels of the ER-associated stress and apoptosis marker CHOP (Fig. S4C). 
For each condition, three biological replicates were performed and a total of ≥40 cells were counted. Box plots are 
drawn from the first to third quartile and the median value is marked by a horizontal line. Whiskers extend to the 
minimum and maximum values. *p < 0.05, **p < 0.005, ***p < 0.0005, not significant (ns) p > 0.05.
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Localization and utilization of cellular p97. Using a combination of immunofluorescence and cellular frac-
tionation, we compared the cellular distribution of p97 in MCF-10A and MCF-7 cells. When treated with p97i, each cell 
line showed distinct patterns of p97 localization (Figs 3 and 4). At lower doses, these patterns provide a snapshot of the 
location and relative abundance of p97 substrates that interact with and sequester inhibited p97. At higher doses, p97 
localization is likely dictated by the onset of apoptotic signals (Fig. S4A,B) that promote chromatin decondensation and 
nuclear collapse65. Compared to MCF-10A, MCF-7 cells showed a significant increase in nuclear and chromatin-bound 
p97 (Figs 3 and 4), suggesting that MCF-7 cells rely more heavily on p97 to manage chromosomal stress associated with 
rapid cell growth and proliferation. MCF-7 cells are also aneuploid (with the number of chromosomes found in each 
cell ranging from 60 to 14066–68), which could increase the frequency of p97-associated chromatin extraction events 
generated during cell cycle progression and in response to stress. These results support the idea that p97 represents an 
attractive target for therapeutic intervention that could provide selectivity during anti-cancer treatments28,69.
Connecting p97 defects with disease etiology. To investigate p97 mutations found in the clinic, we 
supplemented extract with one of the most common p97 mutants, R155C40, and analyzed its effect on chroma-
tin extraction. We found that p97-R155C had a dominant negative effect on the accumulation of DNA-bound 
ubiquitin and p97 (Fig. 5A, lanes 10–13), indicating a functional defect in chromatin extraction. These results are 
consistent with previous studies showing that some p97 mutations associated with neurodegenerative diseases 
also led to an accumulation of ubiquitinated proteins61–63. We also observed similar defects when p97’s ATPase 
activity was inhibited with CB-5083 (Fig. 1A, lanes 6–9) or NMS-873 (Fig. S2, lanes 6–9), and when p97’s D1 
and D2 ATPase domains were mutated (Fig. 5A, lanes 6–9). However, by uncoupling rather than disabling p97’s 
ATPase activity, the R155C mutation also created additional defects (Fig. 5A, lanes 10–13) that were relieved by 
the addition of excess ATP (Fig. 5D, lanes 7–8). As such, p97-R155C likely binds to ubiquitinated substrates and 
promotes excessive ATP hydrolysis in a futile attempt to extract the protein. In our system, these defects were 
observed in the presence of elevated p97 levels and affected what is likely the most ATP-dependent event - chro-
matinization. However, in cells, excess ATP consumption more likely leads to chronic issues that affect multiple 
cellular processes. In Drosophila, defects associated with several p97 mutations (R155H, R191Q, and A232E) 
were relieved by increasing ATP levels45, suggesting that excess ATP consumption is a common factor in disease 
Figure 4. Fractionation reveals p97 accumulation in specific cellular compartments. (A) MCF-7 and (B) MCF-
10A cells were each plated for 24 hours and then treated with increasing amounts of CB-5083 (p97i). 24 hours 
after treatment, cells were collected and fractionated into cytoplasmic, soluble nuclear, and chromatin-bound 
fractions. Proteins from each fraction were then visualized by Western blot with the indicated antibodies. Actin 
and Histone H3 serve as loading controls for the indicated fractions. Full Western blot images are available 
in Fig. S5. (C–E) Relative quantitation of p97 accumulation in (C) cytoplasmic, (D) soluble nuclear, and (E) 
chromatin-bound fractions from three biological replicates. Values are normalized to total p97 levels (Fig. S4) 
and error bars represent +/− one standard deviation.
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etiology. Together, the combination of defects observed with p97 mutations may explain why disease primarily 
affects high energy-consuming organs and tissues43, where the requirement for both p97 function and ATP are 
highest.
Treatment of p97-associated disease. Despite p97’s naturally high abundance in cells70, many cancers 
may become increasingly reliant on p97 function to manage elevated stress associated with tumorigenesis69,71. 
Indeed, targeting p97 has been shown to induce apoptosis in multiple cancer cell lines and solid tumor mouse 
models27,32,33,72. p97 inhibitors also show promise for treatment of multiple myeloma, either as a single agent or 
in combination with proteasomal inhibitors72,73. For neurodegenerative diseases associated with p97 mutation, 
inhibiting ATP hydrolysis could influence p97 activity in different ways. For example, in this report, we show that 
R155C uncouples ATP hydrolysis from chromatin extraction. Although p97 inhibition could relieve defects asso-
ciated with excess ATP consumption, it may also exacerbate the dominant negative effects of ATPase inactivation. 
However, p97 inhibition was recently shown to suppress several mitochondrial defects associated with p97 muta-
tions R155H and A232E, suggesting a balance can be reached that provides therapeutic value74. Collectively, our 
results clarify the consequences of one of the most common p97 mutations and describe how protein dysfunction 
may contribute to disease etiology. Understanding the role that p97 plays in enabling or preventing different dis-
eases will provide a rationale for targeting specific mechanisms during treatment.
Methods
DNA incubation in Xenopus egg extracts. Xenopus egg extracts were prepared as described previ-
ously75. Plasmid DNA was incubated in nucleoplasmic extract (NPE) at a final concentration of 50 ng/μL at 21 °C. 
Plasmids used in this study do not contain DNA damage and are not replicated during the reaction due to the 
absence of licensing in a high-speed supernatant (HSS) extract46. Where indicated, reactions were supplemented 
with: 150 mM NMS-873 (ApexBio Technology), 500 mM CB-5083 (PharmaBlock Sciences), 150 μM Ubiquitin 
Figure 5. p97-R155C is functionally defective for chromatin extraction. (A) pDNA was incubated in extract 
supplemented with p97-WT, p97-D1D2, or p97-R155C. DNA-bound proteins were isolated by plasmid pull-
down at various times and visualized by Western blot with the indicated antibodies. Note that p97 antibodies 
recognize both endogenous and recombinant proteins. (B,C) Relative quantitation of total DNA-bound p97 
(B) and ubiquitin (C) from three biological replicates. Values are normalized to peak accumulation in the 
+p97-WT reaction and error bars represent +/− one standard deviation. Full Western blot images are available 
in Fig. S7.
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Vinyl Sulfone (Boston Biochem), 50 μM recombinant ubiquitin (Boston Biochem), or 40 ng/μL recombinant p97. 
All experiments were performed three or more times and representative results are shown. Experiments involving 
vertebrate animals (Xenopus laevis) were performed in accordance with all guidelines and regulations using an 
approved protocol administered by the Medical University of South Carolina Institutional Animal Care and Use 
Committee (IACUC).
Plasmid pull-down. Isolation of plasmids from extract was performed as described previously12. Briefly, 
streptavidin-coupled magnetic beads (Dynabeads M-280, Invitrogen) were washed three times with Tris Buffer 
(50 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA pH 8, 0.02% Tween-20). Biotinylated LacI was then added to 
beads (12 pmol of LacI per 6 μL beads) and rotated at 21 °C for 40 minutes. The beads were washed four times 
with Pull-Down Buffer (10 mM Hepes pH 7.7, 50 mM KCl, 2.5 mM MgCl2, 250 mM sucrose, 0.25 mg/ml BSA, 
0.02% Tween-20) and then stored at 4 °C until use. At the indicated time points, reaction samples were added to 
LacI-coupled magnetic beads and rotated for 20 minutes at 4 °C. Beads were then washed three times with 250 μL 
of Wash Buffer (10 mM HEPES pH 2.7, 50 mM KCl, 2.5 mM MgCl2, 0.25 mg/ml BSA, and 0.03% Tween 20), 
dried, and resuspended in 2× SDS Sample Buffer (100 mM Tris-HCl pH 6.8, 4% SDS, 0.2% bromophenol blue, 
Figure 6. p97-R155C does not utilize ATP for DNA displacement. (A–D) pDNA was incubated in extract 
supplemented with p97-WT (A), p97-D1D2 (B), or p97-R155C (C). After 180 minutes, DNA was isolated 
by plasmid pull-down and then incubated in buffer +/− ATP. At various times, DNA-bound proteins were 
recovered and visualized by Western blot with the indicated antibodies. (D) Quantitation of DNA-bound p97 
from three biological replicates. Values are normalized to accumulation after pre-incubation with recombinant 
p97-WT (0 minutes) and error bars represent +/− one standard deviation. Full Western blot images are 
available in Fig. S8.
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20% glycerol, and 200 mM β-mercaptoethanol). Plasmid-bound proteins were resolved by SDS-polyacrylamide 
gel electrophoresis (PAGE) and visualized by Western blotting with the indicated antibodies.
For dilution experiments, plasmids were incubated in extract for 180 minutes, isolated by plasmid pull-down, 
washed three times with Lac I wash buffer, and then resuspended in 100 volumes of Egg Lysis Buffer (ELB: 10 mM 
HEPES-KOH pH 7.7, 2.5 mM MgCl2, 50 mM KCl, 250 mM sucrose, and 1 mM DTT) supplemented with 5 mM 
ATP and/or 500 mM CB-5083 as indicated. After dilution, reactions were incubated at 21 °C for the indicated 
time, dried, and resuspended in 2xSDS Sample Buffer for analysis by Western blot. The following antibodies were 
used in this study: p97 (#612182) from BD Biosciences, histone H3 (#PA5-16183) from Thermo Fisher, ubiquitin 
(#PA1-187) from Pierce Biotechnology, actin (ab1801) from Abcam, and Aurora-B (A300-431AT) from Bethyl 
Laboratories.
Protein expression and purification. Expression constructs for Xenopus laevis wild-type His6-p97 
and the D1D2 ATPase-inactive mutant (E305Q and E578Q) were provided by Olaf Stemmann (University 
of Bayreuth)76. The R155C mutation was introduced by Quikchange site-directed mutagenesis (Agilent 
Technologies) using the following primers:
Forward 5′-GGTGACATTTTCCTGGTACTTGGAGGGATGAGAGCC-3′
Reverse 5′-GGCTCTCATCCCTCCAAGTACCAGGAAAATGTCACC-3′
Recombinant proteins were purified as described previously76,77. Briefly, bacterially expressed proteins were 
bound to Ni-NTA-agarose (Life Technologies), eluted with NTA Elution Buffer (1 mM MgCl2, 100 mM KCl, 
150 mM sucrose, 5 mM HEPES-KOH pH 7.4, 250 mM imidazole, 1 mM DTT), dialyzed against ELB, and then 
snap frozen for storage at −80 °C.
ATPase activity assay. The ATPase activity of recombinant p97 was measured using the ADP-Glo® 
Luminescent Kinase Assay (Promega). 500 μg of recombinant p97 (WT, D1D2, or R155C) was incubated in 
25 μL of ELB containing 0.1 mM ATP with or without 0.1 mM CB-5083 at 21 °C. At the indicated times, 5 μL 
from each reaction was mixed with 5 μL of ADP-Glo reagent, and then incubated at 21 °C. After 40 minutes. 
10 μL of the Kinase Detection reagent was added and samples were incubated at 21 °C an additional 40 minutes. 
Luminescence from the converted ATP was then measured using a FilterMax F5 Multi-mode microplate reader 
(Molecular Devices).
Imaging by immunofluorescence. MCF-7 and MCF-10A cells were seeded onto coverslips in 6-well 
(34.8 mm) plates at a density of 10,000 cells per well. Cells were allowed to adhere to coverslips for 24 hours and 
then treated with increasing doses of CB-5083 or a DMSO buffer control. 24 hours after drug treatment, cells were 
fixed for 10 minutes in 4% paraformaldehyde in PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.47 mM 
KH2PO4, and pH adjusted to 7.4). Cells were then washed three times with PBS, incubated 1 hour with blocking 
buffer (5% FBS, 1% BSA, 0.2% Triton X-100 in PBS), and then incubated overnight with blocking buffer contain-
ing 1:500 anti-VCP antibodies (Fisher BDB612182). Cells were washed three times in PBS, incubated 1 hour with 
PBS containing 1:500 Alexa Fluor-488 (Fisher A-21202) secondary antibody, washed twice with PBS, and then 
mounted on slides using Vectashield containing DAPI (Vector). Z-stacked images of nuclei were taken with a step 
size of 1 μm using an Olympus FV10i LV laser scanning confocal microscope. Images were analyzed using FIJI. 
Z-stacked images were used to create a maximum Z projection and the pixel intensity was quantified. The rela-
tive fraction of nuclear p97 was represented as the total nuclear pixel intensity (average intensity x total nuclear 
area) divided by the total cellular pixel intensity (average intensity × total cellular area) normalized to the mean 
in buffer-treated cells. For cell clusters, nuclear and total intensities were determined in aggregate and used to 
determine the average abundance of each cell in the group.
Cellular fractionation. MCF-7 and MCF-10A cells were obtained from ATCC and cultured according to their 
specifications. Two million cells were plated in 10 cm dishes for 24 hours, and then treated with fresh media contain-
ing the indicated concentration of CB-5083 or a DMSO buffer control. After 24 hours, treated cells were harvested 
with 0.5% trypsin-EDTA, washed with cold PBS and then fractionated using the Subcellular Protein Fractionation Kit 
(Thermo Scientific). Total samples of whole cell lysates were also prepared by resuspending pelleted cells in 2× SDS 
Sample Buffer. Proteins were resolved by SDS-PAGE and visualized by Western blotting with the indicated antibodies.
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